Latest News and Press Releases

Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with...

Le recrutement d’un Directeur Financier, d’une Directrice Juridique et d’une Directrice des Ressources Humaines reflète le renforcement de l’organisation d’Inventiva à mesure que la société se prépare...

Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes...

Company announcement – No. 9 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Hydros resultat for første kvartal 2026 blir offentliggjort 29. april 2026 kl. 07.00 CEST (01.00 EDT, 06.00 BST, 05.00 UTC/GMT). Kvartalsrapporten og presentasjonsmaterialet blir gjort tilgjengelig...

Hydro's first quarter results 2026 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on April 29, 2026. The quarterly report and presentation will be available on hydro.com at the...

Medlemmer av Hydros konsernledelse har mottatt aksjer i Hydros langtidsinsentivprogram og kjøpt aksjer via aksjekjøpsprogram for ansatte. Langtidsinsentivprogrammet Norsk Hydro ASA har et...

Members of Hydro’s Executive Leadership Team have received shares in Hydro via the Long-Term Incentive plan and purchased shares via the employee share purchase program. Long-Term Incentive plan ...

Sveitarfélagið Árborg – Ársreikningur 2025 Ársreikningur Sveitarfélagsins Árborgar fyrir árið 2025 var lagður fram í bæjarráði og til fyrri umræðu á fundi bæjarstjórnar í dag miðvikudaginn...